companies developing glp 1 drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog companies developing glp-1 drugs Beyond
Description
As a first-in-class bispecific molecule, MariTide combines a GLP-1 receptor agonist with a GIP receptor antagonist, leveraging a unique dual mechanism that is reshaping expectations for medical weight loss
doi: 10.1016/j.ygcen.2017.12.007 154 ZengXXieYJLiuYTLongSLMoZC
The chief medical officer for England, Prof Chris Whitty, recently argued against prescriptions being viewed as an alternative to the policies promoting healthier food that he believes are urgently needed
Contemporary medical, device, and surgical therapies for obesity in adults
Recent mergers and acquisitions have also shaped the landscape
